IL289946B2 - Bispecific antibodies against CD3 and CD20 - Google Patents

Bispecific antibodies against CD3 and CD20

Info

Publication number
IL289946B2
IL289946B2 IL289946A IL28994622A IL289946B2 IL 289946 B2 IL289946 B2 IL 289946B2 IL 289946 A IL289946 A IL 289946A IL 28994622 A IL28994622 A IL 28994622A IL 289946 B2 IL289946 B2 IL 289946B2
Authority
IL
Israel
Prior art keywords
seq
region
antibody
sequence
amino acid
Prior art date
Application number
IL289946A
Other languages
English (en)
Hebrew (he)
Other versions
IL289946A (en
IL289946B1 (en
Original Assignee
Genmab As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56355550&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL289946(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/EP2015/050276 external-priority patent/WO2015104346A1/en
Application filed by Genmab As filed Critical Genmab As
Publication of IL289946A publication Critical patent/IL289946A/en
Publication of IL289946B1 publication Critical patent/IL289946B1/en
Publication of IL289946B2 publication Critical patent/IL289946B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
IL289946A 2015-01-08 2016-01-08 Bispecific antibodies against CD3 and CD20 IL289946B2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
PCT/EP2015/050276 WO2015104346A1 (en) 2014-01-09 2015-01-08 Humanized or chimeric cd3 antibodies
DKPA201500413 2015-07-15
DKPA201500412 2015-07-15
DKPA201500416 2015-07-16
DKPA201500415 2015-07-16
PCT/EP2016/050296 WO2016110576A1 (en) 2015-01-08 2016-01-08 Bispecific antibodies against cd3 and cd20

Publications (3)

Publication Number Publication Date
IL289946A IL289946A (en) 2022-03-01
IL289946B1 IL289946B1 (en) 2025-02-01
IL289946B2 true IL289946B2 (en) 2025-06-01

Family

ID=56355550

Family Applications (3)

Application Number Title Priority Date Filing Date
IL289946A IL289946B2 (en) 2015-01-08 2016-01-08 Bispecific antibodies against CD3 and CD20
IL318350A IL318350A (en) 2015-01-08 2016-01-08 Bispecific antibodies against cd3 and cd20
IL253166A IL253166B (en) 2015-01-08 2017-06-25 Bispecific antibodies against cd3 and cd20

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL318350A IL318350A (en) 2015-01-08 2016-01-08 Bispecific antibodies against cd3 and cd20
IL253166A IL253166B (en) 2015-01-08 2017-06-25 Bispecific antibodies against cd3 and cd20

Country Status (13)

Country Link
US (2) US10544220B2 (enExample)
EP (2) EP4678661A3 (enExample)
JP (3) JP6853176B2 (enExample)
KR (3) KR20240148942A (enExample)
CN (2) CN107660214B (enExample)
AU (3) AU2016205967B2 (enExample)
CA (1) CA2973159A1 (enExample)
EA (1) EA201791554A1 (enExample)
IL (3) IL289946B2 (enExample)
MX (2) MX391279B (enExample)
SG (1) SG11201705496SA (enExample)
UA (1) UA120286C2 (enExample)
WO (1) WO2016110576A1 (enExample)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3434767T (pt) * 2010-11-30 2026-01-23 Chugai Pharmaceutical Co Ltd Agente terapêutico indutor de citotoxicidade
AU2013285355A1 (en) 2012-07-06 2015-01-29 Genmab B.V. Dimeric protein with triple mutations
HUE048722T2 (hu) 2013-07-05 2020-08-28 Genmab As Humanizált vagy kiméra CD3 ellenanyagok
KR102225489B1 (ko) 2013-12-17 2021-03-10 제넨테크, 인크. 항-cd3 항체 및 이의 사용 방법
SG11201701627PA (en) 2014-09-12 2017-03-30 Genentech Inc Anti-cll-1 antibodies and immunoconjugates
EP3916018A1 (en) 2015-06-16 2021-12-01 Genentech, Inc. Anti-cd3 antibodies and methods of use
TW201718647A (zh) 2015-06-16 2017-06-01 建南德克公司 抗-cll-1抗體及使用方法
ES2957567T3 (es) 2015-06-16 2024-01-22 Hoffmann La Roche Anticuerpos humanizados y de afinidad madurada contra FcRH5 y procedimientos de uso
AU2016293073B2 (en) 2015-07-15 2022-12-22 Genmab A/S Humanized or chimeric CD3 antibodies
IL319047A (en) 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
CA3059010A1 (en) * 2016-06-02 2018-12-06 F. Hoffmann-La Roche Ag Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
EP3252078A1 (en) * 2016-06-02 2017-12-06 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
JP7083819B2 (ja) * 2016-09-30 2022-06-13 セントレ ナショナル デ ラ レセルシュ シャンティフィク 細胞マーカー
US11466094B2 (en) * 2016-11-15 2022-10-11 Genentech, Inc. Dosing for treatment with anti-CD20/anti-CD3 bispecific antibodies
KR102692708B1 (ko) 2016-12-20 2024-08-07 에프. 호프만-라 로슈 아게 항-cd20/항-cd3 이중특이성 항체 및 4-1bb(cd137) 작용물질의 병용 요법
EP3661555B1 (en) 2017-08-01 2025-04-16 Ab Therapeutics, Inc. Bispecific antibodies and uses thereof
WO2019025545A1 (en) * 2017-08-04 2019-02-07 Genmab A/S BINDING AGENTS BINDING TO PD-L1 AND CD137 AND THEIR USE
EP3668898B1 (en) 2017-08-14 2023-07-05 MorphoSys AG Humanized antibodies for cd3
CN107501412A (zh) * 2017-10-11 2017-12-22 深圳精准医疗科技有限公司 突变型双特异性抗体及其应用
CN118772287A (zh) 2018-02-08 2024-10-15 豪夫迈·罗氏有限公司 双特异性抗原结合分子和使用方法
JP7326345B2 (ja) * 2018-02-09 2023-08-15 ジェンマブ アクティーゼルスカブ Ｃｄ３及びｃｄ２０に対する二重特異性抗体を含む医薬組成物及びそれらの使用
CA3093330A1 (en) * 2018-03-14 2019-09-19 Novimmune Sa Anti-cd3 epsilon antibodies and methods of use thereof
EP3569617A1 (en) * 2018-05-18 2019-11-20 Trion Research GmbH Pharmaceutical preparation for use in treating epstein- barr virus positive patients with reactivation phenomenon- associated diseases
CN110540593B (zh) * 2018-05-29 2022-05-17 上海药明生物技术有限公司 新型的抗cd3/抗cd20双特异性抗体
WO2019244107A1 (en) * 2018-06-21 2019-12-26 Daiichi Sankyo Company, Limited Compositions including cd3 antigen binding fragments and uses thereof
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
CN109836502B (zh) * 2018-11-12 2021-09-07 浙江大学 一种双特异性抗体及其应用
US12463463B2 (en) 2019-01-28 2025-11-04 Ab Therapeutics, Inc. Bispecific antibodies and uses thereof
WO2020168555A1 (zh) * 2019-02-22 2020-08-27 武汉友芝友生物制药有限公司 Cd3抗原结合片段及其应用
EP3969907B1 (en) * 2019-05-13 2025-09-24 F. Hoffmann-La Roche AG Interference-suppressed pharmacokinetic immunoassay
CN110551221B (zh) * 2019-07-02 2021-03-05 广州爱思迈生物医药科技有限公司 一种双特异性抗体及其制备方法与应用
UA128416C2 (uk) * 2019-08-15 2024-07-03 Генмаб А/С Фармацевтичні композиції, які містять біспецифічні антитіла проти cd3 і cd20, та їх застосування
CN111100204B (zh) * 2019-11-26 2022-03-11 山东立菲生物产业有限公司 靶向cd20的抗体、其制备方法和应用
PE20221511A1 (es) 2019-12-13 2022-10-04 Genentech Inc Anticuerpos anti-ly6g6d y metodos de uso
EP4090377A1 (en) * 2020-01-13 2022-11-23 Synaffix B.V. Conjugates of antibodies an immune cell engagers
CN113402612A (zh) * 2020-03-17 2021-09-17 西比曼生物科技（香港）有限公司 靶向cd19和cd20的联合嵌合抗原受体及其应用
CA3168613A1 (en) * 2020-03-18 2021-09-23 Genmab A/S Antibodies binding to b7h4
CA3176436A1 (en) 2020-05-08 2021-11-11 Tahamtan Ahmadi Bispecific antibodies against cd3 and cd20
US11976120B2 (en) 2020-06-01 2024-05-07 Boehringer Ingelheim International Gmbh Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use
US10981996B1 (en) 2020-06-01 2021-04-20 Abexxa Biologics, Inc. Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use
CN112062855B (zh) * 2020-08-26 2024-08-30 北京天诺健成医药科技有限公司 一种含有衔接器的药物治疗剂的开发和应用
AU2021342343A1 (en) * 2020-09-10 2023-04-13 Genmab A/S Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
CN116406293A (zh) 2020-09-10 2023-07-07 健玛保 用于治疗滤泡性淋巴瘤的联合疗法中的针对cd3和cd20的双特异性抗体
JP2023542291A (ja) * 2020-09-10 2023-10-06 ジェンマブ エー／エス びまん性大細胞型ｂ細胞リンパ腫を治療するための併用療法におけるｃｄ３及びｃｄ２０に対する二重特異性抗体
US20240034812A1 (en) 2020-09-10 2024-02-01 Genmab A/S Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
JP2023542289A (ja) 2020-09-10 2023-10-06 ジェンマブ エー／エス 濾胞性リンパ腫を治療するための併用療法におけるｃｄ３及びｃｄ２０に対する二重特異性抗体
JP2023541858A (ja) * 2020-09-10 2023-10-04 ジェンマブ エー／エス 慢性リンパ球性白血病を治療するためのｃｄ３及びｃｄ２０に対する二重特異性抗体
CA3196539A1 (en) 2020-11-04 2022-05-12 Chi-Chung Li Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
IL302400A (en) 2020-11-04 2023-06-01 Genentech Inc Subcutaneous dosing of bispecific anti-CD20/anti-CD3 antibodies
CA3196191A1 (en) 2020-11-04 2022-05-12 Chi-Chung Li Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates
CN114656562B (zh) 2020-12-23 2023-11-03 北京天广实生物技术股份有限公司 结合人和猴cd3的抗体及其应用
SI4284512T1 (sl) 2021-01-28 2025-06-30 Regeneron Pharmaceuticals, Inc. Sestavki in postopki za zdravljenje sindroma sproščanja citokinov
US20240139322A1 (en) * 2021-03-10 2024-05-02 H. Lee Moffitt Cancer Center And Research Institute Inc. Compositions and methods to reduce therapeutic t cell toxicity
CA3210971A1 (en) * 2021-03-12 2022-09-15 Bart-Jan DE KREUK Non-activating antibody variants
AU2021443318A1 (en) 2021-04-30 2023-09-07 F. Hoffmann-La Roche Ag Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
WO2022241235A1 (en) 2021-05-14 2022-11-17 Genentech, Inc. Methods for treatment of cd20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin
MX2024008832A (es) 2022-01-28 2024-07-25 Genmab As Anticuerpo biespecifico contra el cumulo de diferenciacion 3 (cd3) y el cumulo de diferenciacion 20 (cd20) en terapia combinada para tratar linfoma difuso de celulas b grandes.
WO2023144290A1 (en) 2022-01-28 2023-08-03 Genmab A/S Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
US20230357446A1 (en) 2022-04-11 2023-11-09 Regeneron Pharmaceuticals, Inc. Compositions and methods for universal tumor cell killing
US20250304689A1 (en) 2022-04-13 2025-10-02 Genmab A/S Bispecific antibodies against cd3 and cd20
WO2023201291A1 (en) 2022-04-13 2023-10-19 Genentech, Inc. Pharmaceutical compositions of mosunetuzumab and methods of use
WO2024102948A1 (en) 2022-11-11 2024-05-16 Celgene Corporation Fc receptor-homolog 5 (fcrh5) specific binding molecules and bispecific t-cell engaging antibodies including same and related methods
CA3277013A1 (en) * 2022-12-14 2024-06-20 Evolveimmune Therapeutics, Inc. BISPECIFIC ANTIBODY FUSION MOLECULES AND THEIR METHODS OF USE
IL322545A (en) 2023-02-17 2025-10-01 Regeneron Pharma Induced NK cells responding to bispecific CD3/TAA antibodies
AU2024244733B2 (en) 2023-03-31 2025-12-11 AbelZeta Inc. Bispecific chimeric antigen receptors targeting cd20 and bcma
US20240368297A1 (en) 2023-04-13 2024-11-07 Genmab A/S Methods of treating lymphoma with bispecific antibodies against cd3 and cd20
IL324480A (en) 2023-05-15 2026-01-01 Genmab As Highly purified epcoritamab compositions
KR20260013467A (ko) 2023-05-15 2026-01-28 젠맵 에이/에스 Cd20 발현 b-세포 암을 치료하는 방법
AU2024346729A1 (en) * 2023-09-20 2026-03-19 Evolveimmune Therapeutics, Inc. Bispecific antibody fusion molecules targeting cd180 and cd3 and methods of use thereof
WO2025109119A1 (en) * 2023-11-22 2025-05-30 Priothera Sas Methods of treatment with multispecific antigen-binding proteins in combination with s1p receptor modulators
GB2641580A (en) 2024-06-07 2025-12-10 T Therapeutics Ltd Tumour-transforming multispecific proteins

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012162067A2 (en) * 2011-05-21 2012-11-29 Macrogenics, Inc. Cd3-binding molecules capable of binding to human and non-human cd3
US20140088295A1 (en) * 2012-09-21 2014-03-27 Regeneron Pharmaceuticals, Inc. Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077A (en) 1849-01-30 Improved hinged claw-wrench
US835A (en) 1838-07-12 X i i i x
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
KR970029803A (ko) 1995-11-03 1997-06-26 김광호 반도체 메모리장치의 프리차지 회로
DK0979281T3 (da) 1997-05-02 2005-11-21 Genentech Inc Fremgangsmåde til fremstilling af multispecifikke antistoffer med heteromultimere og fælles bestanddele
CA2347067C (en) 1998-03-31 2013-09-17 Geron Corporation Dendritic cell vaccine containing telomerase reverse transcriptase for the treatment of cancer
DE60013773T2 (de) 1999-02-03 2005-11-10 Biosante Pharmaceuticals, Inc. Methoden zur Herstellung von therapeutischen Kalziumphosphat Partikeln
US6281005B1 (en) 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
US6713055B2 (en) 2000-11-27 2004-03-30 Geron Corporation Glycosyltransferase vectors for treating cancer
US20100081792A1 (en) 2001-06-28 2010-04-01 Smithkline Beecham Corporation Ligand
CA2478011C (en) 2002-03-01 2013-05-21 Immunomedics, Inc. Bispecific antibody point mutations for enhancing rate of clearance
PT2314629E (pt) 2002-07-18 2014-01-22 Merus B V Produção recombinante de misturas de anticorpos
PL216630B1 (pl) * 2002-10-17 2014-04-30 Genmab As Izolowane ludzkie przeciwciało monoklonalne wiążące ludzki CD20, związane z tym przeciwciałem transfektoma, komórka gospodarza, transgeniczne zwierzę lub roślina, kompozycja, immunokoniugat, cząsteczka bispecyficzna, wektor ekspresyjny, kompozycja farmaceutyczna, zastosowanie medyczne, zestaw oraz przeciwciało antyidiotypowe i jego zastosowanie
US20050100543A1 (en) 2003-07-01 2005-05-12 Immunomedics, Inc. Multivalent carriers of bi-specific antibodies
ES2672640T3 (es) 2003-11-05 2018-06-15 Roche Glycart Ag Moléculas de unión a antígeno con afinidad de unión a receptores Fc y función efectora incrementadas
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
US7741568B2 (en) 2005-01-13 2010-06-22 The Wiremold Company Downward facing receptacle assembly for cable raceway
TWI671403B (zh) 2005-03-31 2019-09-11 中外製藥股份有限公司 控制組裝之多肽的製造方法
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP1940881B1 (en) * 2005-10-11 2016-11-30 Amgen Research (Munich) GmbH Compositions comprising cross-species-specific antibodies and uses thereof
AU2006317242A1 (en) 2005-11-28 2007-05-31 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
GEP20135917B (en) 2006-03-17 2013-09-10 Biogen Idec Inc Stabilized polypeptide compositions
ES2395969T3 (es) 2006-03-24 2013-02-18 Merck Patent Gmbh Dominios de proteínas heterodiméricas genéticamente modificados
AT503902B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von immunglobulinen
EP2139924B1 (en) 2007-03-29 2016-07-06 Genmab A/S Bispecific antibodies and methods for production thereof
WO2008119567A2 (en) 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific cd3-epsilon binding domain
EP2170951A2 (en) * 2007-05-31 2010-04-07 Genmab A/S Recombinant non glycosylated monovalent half-antibodies obtained by molecular engineering
US20100291023A1 (en) * 2007-05-31 2010-11-18 Genmab A/S Method for extending the half-life of exogenous or endogenous soluble molecules
CA2689695A1 (en) * 2007-05-31 2008-12-04 Genmab A/S Transgenic animals producing monovalent human antibodies and antibodies obtainable from these animals
ES2702087T3 (es) 2007-06-21 2019-02-27 Macrogenics Inc Diacuerpos covalentes y sus usos
JP5592792B2 (ja) 2007-09-26 2014-09-17 ユセベ ファルマ ソシエテ アノニム 二重特異性抗体の融合体
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
SI2235064T1 (sl) 2008-01-07 2016-04-29 Amgen Inc. Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov
WO2010015792A1 (en) 2008-08-06 2010-02-11 Argenta Discovery Limited Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors
AU2009299794B2 (en) * 2008-10-01 2015-08-13 Amgen Research (Munich) Gmbh Cross-species-specific single domain bispecific single chain antibody
JP5677972B2 (ja) 2008-11-18 2015-02-25 メリマック ファーマシューティカルズ インコーポレーティッド ヒト血清アルブミンリンカーおよびそのコンジュゲート
SG172254A1 (en) 2008-12-19 2011-07-28 Macrogenics Inc Covalent diabodies and uses thereof
CN102448984A (zh) 2009-03-27 2012-05-09 酶遗传学股份有限公司 使用包含抗体-受体组合的多特异性结合蛋白的组合物和方法
CN102459346B (zh) 2009-04-27 2016-10-26 昂考梅德药品有限公司 制造异源多聚体分子的方法
KR101224468B1 (ko) 2009-05-20 2013-01-23 주식회사 파멥신 신규한 형태의 이중표적항체 및 그 용도
UY32808A (es) 2009-07-29 2011-02-28 Abbott Lab Inmunoglobulinas como dominio variable dual y usos de las mismas
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
PL2506871T3 (pl) 2009-11-30 2017-03-31 Janssen Biotech, Inc Przeciwciała ze zmutowanymi regionami Fc i utraconymi funkcjami efektorowymi
MX2012006406A (es) 2009-12-04 2012-07-25 Genentech Inc Anticuerpos multiespecificos, analogos de anticuerpo, composiciones y metodos.
SG181952A1 (en) 2009-12-29 2012-07-30 Emergent Product Dev Seattle Heterodimer binding proteins and uses thereof
TWI426920B (zh) 2010-03-26 2014-02-21 Hoffmann La Roche 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體
PL2560993T3 (pl) 2010-04-20 2024-11-04 Genmab A/S Heterodimeryczne białka zawierające region FC przeciwciała i sposoby ich wytwarzania
CA2797981C (en) 2010-05-14 2019-04-23 Rinat Neuroscience Corporation Heterodimeric proteins and methods for producing and purifying them
RU2608640C2 (ru) 2010-08-16 2017-01-23 Новиммун С.А. Способы получения мультиспецифичных и мультивалентных антител
RU2013110876A (ru) 2010-08-24 2014-09-27 Рош Гликарт Аг Активируемые биспецифические антитела
RU2013110875A (ru) 2010-08-24 2014-09-27 Ф.Хоффманн-Ля Рош Аг БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА, СОДЕРЖАЩИЕ СТАБИЛИЗИРОВАННЫЙ ДИСУЛЬФИДОМ ФРАГМЕНТ Fv
AU2011325833C1 (en) 2010-11-05 2017-07-13 Zymeworks Bc Inc. Stable heterodimeric antibody design with mutations in the Fc domain
PT3434767T (pt) * 2010-11-30 2026-01-23 Chugai Pharmaceutical Co Ltd Agente terapêutico indutor de citotoxicidade
AU2012245116A1 (en) * 2011-04-20 2013-11-07 Genmab A/S Bispecific antibodies against HER2 and CD3
CN102250246A (zh) 2011-06-10 2011-11-23 常州亚当生物技术有限公司 抗VEGF/PDGFRβ双特异性抗体及其应用
PH12013502531A1 (en) 2011-08-23 2014-01-20 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
HUE044633T2 (hu) 2011-10-27 2019-11-28 Genmab As Heterodimer fehérjék elõállítása
DK2838917T3 (da) 2012-04-20 2019-08-26 Merus Nv Fremgangsmåder og midler til frembringelse af heterodimere ig-lignende molekyler
AU2013285355A1 (en) * 2012-07-06 2015-01-29 Genmab B.V. Dimeric protein with triple mutations
ES2744267T3 (es) 2012-11-21 2020-02-24 Pharmabcine Inc Anticuerpo de doble diana que se dirige a VEGFR-2 y DLL4, y composición farmacéutica que comprende el mismo
WO2014131711A1 (en) 2013-02-26 2014-09-04 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
CN110845618A (zh) 2013-02-26 2020-02-28 罗切格利卡特公司 双特异性t细胞活化抗原结合分子
HUE048722T2 (hu) 2013-07-05 2020-08-28 Genmab As Humanizált vagy kiméra CD3 ellenanyagok
US20160355588A1 (en) * 2013-07-12 2016-12-08 Zymeworks Inc. Bispecific CD3 and CD19 Antigen Binding Constructs
KR102225489B1 (ko) * 2013-12-17 2021-03-10 제넨테크, 인크. 항-cd3 항체 및 이의 사용 방법
TWI701042B (zh) 2014-03-19 2020-08-11 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
AU2015350075B2 (en) 2014-11-17 2021-06-03 Regeneron Pharmaceuticals, Inc. Methods for tumor treatment using CD3xCD20 bispecific antibody
EP3464370A1 (en) 2016-06-01 2019-04-10 Xencor, Inc. Bispecific antibodies that bind cd20 and cd3 for use in the treatment of lymphoma
EP3668898B1 (en) * 2017-08-14 2023-07-05 MorphoSys AG Humanized antibodies for cd3
CN116406293A (zh) * 2020-09-10 2023-07-07 健玛保 用于治疗滤泡性淋巴瘤的联合疗法中的针对cd3和cd20的双特异性抗体

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012162067A2 (en) * 2011-05-21 2012-11-29 Macrogenics, Inc. Cd3-binding molecules capable of binding to human and non-human cd3
US20140088295A1 (en) * 2012-09-21 2014-03-27 Regeneron Pharmaceuticals, Inc. Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof

Also Published As

Publication number Publication date
MX391279B (es) 2025-03-21
IL253166B (en) 2022-02-01
IL289946A (en) 2022-03-01
JP7596342B2 (ja) 2024-12-09
BR112017014551A2 (pt) 2018-05-15
AU2016205967A1 (en) 2017-07-27
IL253166A0 (en) 2017-08-31
SG11201705496SA (en) 2017-08-30
EP3242682A1 (en) 2017-11-15
JP2021104020A (ja) 2021-07-26
IL318350A (en) 2025-03-01
AU2022200871B2 (en) 2025-05-08
KR102663073B1 (ko) 2024-05-07
EA201791554A1 (ru) 2017-12-29
US20200199231A1 (en) 2020-06-25
JP2018508188A (ja) 2018-03-29
WO2016110576A1 (en) 2016-07-14
KR20240148942A (ko) 2024-10-11
UA120286C2 (uk) 2019-11-11
KR102712786B1 (ko) 2024-10-04
JP2023002615A (ja) 2023-01-10
CN114478792A (zh) 2022-05-13
CN107660214A (zh) 2018-02-02
AU2022200871A1 (en) 2022-03-03
AU2025213616A1 (en) 2025-08-21
JP7177317B2 (ja) 2022-11-24
KR20170128222A (ko) 2017-11-22
AU2016205967B2 (en) 2021-11-11
CA2973159A1 (en) 2016-07-14
EP4678661A2 (en) 2026-01-14
JP6853176B2 (ja) 2021-03-31
KR20240064746A (ko) 2024-05-13
EP4678661A3 (en) 2026-03-18
US20170355767A1 (en) 2017-12-14
IL289946B1 (en) 2025-02-01
NZ733531A (en) 2024-11-29
CN107660214B (zh) 2022-02-08
MX2017008875A (es) 2017-09-27
MX2022004082A (es) 2022-05-03
US10544220B2 (en) 2020-01-28

Similar Documents

Publication Publication Date Title
AU2022200871B2 (en) Bispecific antibodies against CD3 and CD20
US20240317861A1 (en) Antibodies against pd-l1
HK40074511A (en) Bispecific antibodies against cd3 and cd20
BR122024010593A2 (pt) Método para produzir um anticorpo biespecífico
BR122024010585A2 (pt) Uso de um anticorpo biespecífico
BR122024010593B1 (pt) Método para produzir um anticorpo biespecífico
BR112017014551B1 (pt) Anticorpo, composição farmacêutica, método para detecção da possível ocorrência de reticulação entre células com expressão de cd3 e cd20 em uma amostra derivada de um paciente, e, kit
BR122024010585B1 (pt) Uso de um anticorpo biespecífico
HK40021859A (en) Antibodies against pd-l1
HK40021859B (en) Antibodies against pd-l1